danazol has been researched along with Bright Disease in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (66.67) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bazargan, N; Farhoudi, A; Mahmoudi, M; Pourpak, Z | 1 |
| Endoh, M; Miura, M; Nomoto, Y; Sakai, H; Suga, T; Tomino, Y | 1 |
| Zhang, HY | 1 |
1 trial(s) available for danazol and Bright Disease
| Article | Year |
|---|---|
Effect of danazol on solubilization of immune deposits in patients with IgA nephropathy.
Topics: Clinical Trials as Topic; Complement System Proteins; Danazol; Glomerulonephritis; Humans; Immunoglobulin A; In Vitro Techniques; Kidney Glomerulus; Pregnadienes; Proteinuria; Solubility | 1984 |
2 other study(ies) available for danazol and Bright Disease
| Article | Year |
|---|---|
Two related cases of primary complement deficiency.
Topics: Adult; Anti-Bacterial Agents; Complement C3; Danazol; Dyspnea; Edema; Female; Genetic Diseases, Inborn; Glomerulonephritis; Humans; Male; Meningitis, Pneumococcal; Pedigree; Stanozolol | 2003 |
[Hereditary angioedema with chronic glomerulonephritis].
Topics: Adult; Angioedema; Chronic Disease; Complement C1 Inactivator Proteins; Danazol; Female; Glomerulonephritis; Humans; Male; Middle Aged; Pedigree | 1988 |